Novo Nordisk Just Sued Hims & Hers Over Compounded Semaglutide — What It Means for Patients

The legal battle over compounded GLP-1 drugs just escalated significantly. Novo Nordisk has filed its first known patent infringement lawsuit against a major telehealth company, targeting Hims & Hers over its compounded semaglutide products — both injectable and pill forms.

The lawsuit, reported by the FDA Law Blog in late February 2026, marks a new phase in Novo Nordisk's campaign to shut down the compounded semaglutide market. Previously, the pharmaceutical giant had relied on FDA enforcement pressure and previous civil lawsuits targeting pharmacies and distributors. Suing Hims & Hers — one of the largest telehealth platforms in the country — directly for patent infringement is a more aggressive legal strategy with potentially much larger consequences.

What the Lawsuit Alleges

The patent infringement claims relate to Novo Nordisk's intellectual property covering both the injectable and pill forms of semaglutide. The core allegation, based on earlier related litigation, centers on whether compounded semaglutide uses the same active ingredient as FDA-approved Ozempic and Wegovy — or a meaningfully different compound that doesn't infringe Novo's patents but also can't be marketed as equivalent.

A related class action lawsuit against Hims & Hers (filed separately by consumers) alleges that Hims & Hers' compounded semaglutide "does not have the same active ingredient as Ozempic or Wegovy as advertised." The suit argues that Novo Nordisk uses a specialized biological process to produce extremely pure semaglutide peptides, and that compounded versions do not replicate this.

The FDA Law Blog noted that the government has also been turning up broader pressure on compounding: FDA and HHS enforcement actions in early 2026 represent what the blog calls "a warning shot" against the compounding industry's GLP-1 business.

Why This Is a Big Deal

Hims & Hers is not a small compounding pharmacy. It is a publicly traded company with millions of customers, a major media presence, and until recently a significant portion of its revenue tied to compounded semaglutide. When Novo Nordisk targets a company of this scale with patent litigation, it sends a message to the entire compounded GLP-1 ecosystem.

Patent infringement cases are different from FDA enforcement. They can result in injunctions — court orders that immediately stop a company from selling the allegedly infringing product — as well as substantial financial damages. A successful patent case against Hims & Hers could set a precedent that forces other large telehealth platforms to exit the compounded semaglutide market entirely, even before FDA enforcement deadlines.

Hims & Hers had already removed some semaglutide products following FDA warnings in late 2025. The patent lawsuit adds another legal dimension to the pressure it faces.

The Broader Legal Landscape for Compounded GLP-1s

The compounding industry is fighting back. The Outsourcing Facilities Association (OFA) has sued the FDA over the decision to end the tirzepatide shortage — arguing the determination was "reckless and arbitrary" — mirroring a similar lawsuit over the semaglutide shortage ending. Federal courts are now handling active litigation from multiple directions.

As of early January 2026, there are also 3,063 active product liability lawsuits against Novo Nordisk and other GLP-1 manufacturers over side effects including stomach paralysis (gastroparesis) and vision complications. These are separate from the compounding litigation but add to the complex legal environment surrounding GLP-1 drugs.

Key pending legal questions that will shape the market in 2026:

• Can 503A compounding pharmacies continue to prepare individualized semaglutide doses after the shortage ends, or does the shortage ending eliminate that authority?
• Does Novo Nordisk's patent cover all forms of semaglutide, or only specific formulations?
• Will courts grant injunctions against specific telehealth platforms while the patent cases are litigated?
• Will the OFA's lawsuit over the shortage determination succeed and effectively restore compounding rights?

What This Means If You're Currently on Compounded Semaglutide

If you're currently on compounded semaglutide through a telehealth platform, your supply is not guaranteed to continue. The timeline varies by provider:

• Hims & Hers: Already under legal pressure; some compounded products pulled in 2025. Further discontinuation likely.
• 503A compounding pharmacies (the majority of telehealth providers including Remedy Meds): Operating under a disputed legal framework. FDA enforcement focus has been on 503B outsourcing facilities first. 503A pharmacies preparing individualized prescriptions have more legal protection — for now.
• 503B outsourcing facilities: The FDA's 90-day deadline to stop compounded tirzepatide is the most immediate threat. Semaglutide from 503B facilities faces similar pressure.

The safest positions in this legal environment are telehealth providers working with licensed 503A compounding pharmacies that prepare individualized prescriptions based on specific patient needs — which represents the strongest argument for continued legal operation under current law.

What Patients Should Do Now

1. Know your provider's pharmacy model. Ask whether your compounded semaglutide comes from a 503A or 503B pharmacy. 503A has stronger legal footing for individualized compounding.
2. Discuss a contingency plan with your doctor. If compounded semaglutide becomes unavailable, brand-name options (Wegovy, Ozempic) and the new oral Wegovy pill are alternatives worth understanding now, before you're in a supply crisis.
3. Don't panic-hoard. Stockpiling compounded medication introduces storage and potency risks. Stay informed and respond to actual supply changes, not speculation.
4. Monitor your provider's communications. Any reputable telehealth provider will notify customers proactively if they anticipate supply disruption. If yours has gone silent, that's a yellow flag.

Last updated: March 2026